METTL14/m6A/CEBPD axis: A critical player in chronic cerebral hypoperfusion-associated neuroinflammation

Huanhuan Wang1, Hanshu Zhao1, Jiadi Gao1

  • 1Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, PR China.

PubMed

Insights

Targeting METTL14 reduces neuroinflammation and cognitive decline in vascular dementia. This epigenetic approach suppresses microglial M1 polarization by stabilizing CEBPD mRNA, offering a potential therapy for this condition.

Area of Science:

  • Neuroscience
  • Epigenetics
  • Molecular Biology

Background:

  • Vascular dementia (VaD) involves cognitive decline due to chronic cerebral hypoperfusion (CCH) and neuroinflammation.
  • Microglial M1 polarization is a key driver of CCH-related neuroinflammation, but its epigenetic regulation is not fully understood.
  • N6-methyladenosine (m6A) modification, particularly involving METTL14, and CCAAT enhancer binding protein delta (CEBPD) are implicated in brain inflammation.

Purpose of the Study:

  • To investigate the role of METTL14 in microglial polarization and its impact on chronic cerebral hypoperfusion (CCH) pathology.
  • To elucidate the epigenetic mechanism by which METTL14 influences neuroinflammation and cognitive function in vascular dementia (VaD).

Main Methods:

  • In vitro studies using HMC3 cells treated with LPS/TNF-α to assess METTL14 and CEBPD expression and microglial polarization.
  • In vivo studies using bilateral common carotid artery occlusion (BCCAo)-induced CCH rat models.
  • Short hairpin RNA (shRNA) and adeno-associated virus (AAV) mediated knockdown of METTL14.
  • RNA immunoprecipitation-PCR (RIP-PCR) and m6A-specific immunoprecipitation-PCR (MeRIP-qPCR) to confirm m6A modification and mRNA stability.
  • Assessment of cognitive function using spatial learning and memory and object recognition tests.

Main Results:

  • METTL14 knockdown suppressed LPS/TNF-α-induced M1 polarization in HMC3 cells, reducing pro-inflammatory factors and NF-κB activation.
  • In CCH rats, hippocampal METTL14 and CEBPD levels were elevated.
  • AAV-mediated METTL14 knockdown in CCH rats attenuated neuroinflammation, neuronal apoptosis, and improved cognitive deficits.
  • METTL14 was confirmed to enhance CEBPD mRNA stability through m6A modification, with CEBPD acting as a downstream mediator.

Conclusions:

  • METTL14 knockdown inhibits microglial M1 polarization and neuroinflammation in CCH by impairing CEBPD mRNA stability via m6A modification.
  • This process involves the TLR4/MyD88/NF-κB pathway, leading to alleviation of cognitive impairment in vascular dementia.
  • METTL14 represents a potential epigenetic therapeutic target for vascular dementia.